Repurposing an antidandruff agent to treating cancer: Zinc pyrithione inhibits tumor growth via targeting proteasome-associated deubiquitinases

Chong Zhao, Xin Chen, Changshan Yang, Dan Zang, Xiaoying Lan, Siyan Liao, Peiquan Zhang, Jinjie Wu, Xiaofen Li, Ningning Liu, Yuning Liao, Hongbiao Huang, Xianping Shi, Lili Jiang, Xiuhua Liu, Q. Ping Dou, Xuejun Wang, Jinbao Liu

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The ubiquitin-proteasome system (UPS) plays a central role in various cellular processes through selectively degrading proteins involved in critical cellular functions. Targeting UPS has been validated as a novel strategy for treating human cancer, as inhibitors of the 20S proteasome catalytic activity are currently in clinical use for treatment of multiple myeloma and other cancers, and the deubiquitinase activity associated with the proteasome is also a valid target for anticancer agents. Recent studies suggested that zinc pyrithione, an FDA-approved antidandruff agent, may have antitumor activity, but the detailed molecular mechanisms remain unclear. Here we report that zinc pyrithione (ZnPT) targets the proteasome-associated DUBs (USP14 and UCHL5) and inhibits their activities, resulting in a rapid accumulation of protein-ubiquitin conjugates, but without inhibiting the proteolytic activities of 20S proteasomes. Furthermore, ZnPT exhibits cytotoxic effects against various cancer cell lines in vitro, selectively kills bone marrow cells from leukemia patients ex vivo, and efficiently inhibits the growth of lung adenocarcinoma cancer cell xenografts in nude mice. This study has identified zinc pyrithione, an FDA-approved pharmacological agent with potential antitumor properties as a proteasomal DUB inhibitor.

Original languageEnglish (US)
Pages (from-to)13942-13956
Number of pages15
JournalOncotarget
Volume8
Issue number8
DOIs
StatePublished - Jan 1 2017

Fingerprint

Proteasome Endopeptidase Complex
Growth
Ubiquitin
Neoplasms
Multiple Myeloma
Heterografts
Nude Mice
Bone Marrow Cells
Antineoplastic Agents
pyrithione zinc
Deubiquitinating Enzymes
Lung Neoplasms
Leukemia
Proteins
Pharmacology
Cell Line

Keywords

  • DNA damage
  • Deubiquitinases
  • Proteasome
  • Tumor
  • Zinc pyrithione

ASJC Scopus subject areas

  • Oncology

Cite this

Repurposing an antidandruff agent to treating cancer : Zinc pyrithione inhibits tumor growth via targeting proteasome-associated deubiquitinases. / Zhao, Chong; Chen, Xin; Yang, Changshan; Zang, Dan; Lan, Xiaoying; Liao, Siyan; Zhang, Peiquan; Wu, Jinjie; Li, Xiaofen; Liu, Ningning; Liao, Yuning; Huang, Hongbiao; Shi, Xianping; Jiang, Lili; Liu, Xiuhua; Ping Dou, Q.; Wang, Xuejun; Liu, Jinbao.

In: Oncotarget, Vol. 8, No. 8, 01.01.2017, p. 13942-13956.

Research output: Contribution to journalArticle

Zhao, C, Chen, X, Yang, C, Zang, D, Lan, X, Liao, S, Zhang, P, Wu, J, Li, X, Liu, N, Liao, Y, Huang, H, Shi, X, Jiang, L, Liu, X, Ping Dou, Q, Wang, X & Liu, J 2017, 'Repurposing an antidandruff agent to treating cancer: Zinc pyrithione inhibits tumor growth via targeting proteasome-associated deubiquitinases', Oncotarget, vol. 8, no. 8, pp. 13942-13956. https://doi.org/10.18632/oncotarget.14572
Zhao, Chong ; Chen, Xin ; Yang, Changshan ; Zang, Dan ; Lan, Xiaoying ; Liao, Siyan ; Zhang, Peiquan ; Wu, Jinjie ; Li, Xiaofen ; Liu, Ningning ; Liao, Yuning ; Huang, Hongbiao ; Shi, Xianping ; Jiang, Lili ; Liu, Xiuhua ; Ping Dou, Q. ; Wang, Xuejun ; Liu, Jinbao. / Repurposing an antidandruff agent to treating cancer : Zinc pyrithione inhibits tumor growth via targeting proteasome-associated deubiquitinases. In: Oncotarget. 2017 ; Vol. 8, No. 8. pp. 13942-13956.
@article{9eea7f666e6048e2a3d092f5e152ca1e,
title = "Repurposing an antidandruff agent to treating cancer: Zinc pyrithione inhibits tumor growth via targeting proteasome-associated deubiquitinases",
abstract = "The ubiquitin-proteasome system (UPS) plays a central role in various cellular processes through selectively degrading proteins involved in critical cellular functions. Targeting UPS has been validated as a novel strategy for treating human cancer, as inhibitors of the 20S proteasome catalytic activity are currently in clinical use for treatment of multiple myeloma and other cancers, and the deubiquitinase activity associated with the proteasome is also a valid target for anticancer agents. Recent studies suggested that zinc pyrithione, an FDA-approved antidandruff agent, may have antitumor activity, but the detailed molecular mechanisms remain unclear. Here we report that zinc pyrithione (ZnPT) targets the proteasome-associated DUBs (USP14 and UCHL5) and inhibits their activities, resulting in a rapid accumulation of protein-ubiquitin conjugates, but without inhibiting the proteolytic activities of 20S proteasomes. Furthermore, ZnPT exhibits cytotoxic effects against various cancer cell lines in vitro, selectively kills bone marrow cells from leukemia patients ex vivo, and efficiently inhibits the growth of lung adenocarcinoma cancer cell xenografts in nude mice. This study has identified zinc pyrithione, an FDA-approved pharmacological agent with potential antitumor properties as a proteasomal DUB inhibitor.",
keywords = "DNA damage, Deubiquitinases, Proteasome, Tumor, Zinc pyrithione",
author = "Chong Zhao and Xin Chen and Changshan Yang and Dan Zang and Xiaoying Lan and Siyan Liao and Peiquan Zhang and Jinjie Wu and Xiaofen Li and Ningning Liu and Yuning Liao and Hongbiao Huang and Xianping Shi and Lili Jiang and Xiuhua Liu and {Ping Dou}, Q. and Xuejun Wang and Jinbao Liu",
year = "2017",
month = "1",
day = "1",
doi = "10.18632/oncotarget.14572",
language = "English (US)",
volume = "8",
pages = "13942--13956",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "8",

}

TY - JOUR

T1 - Repurposing an antidandruff agent to treating cancer

T2 - Zinc pyrithione inhibits tumor growth via targeting proteasome-associated deubiquitinases

AU - Zhao, Chong

AU - Chen, Xin

AU - Yang, Changshan

AU - Zang, Dan

AU - Lan, Xiaoying

AU - Liao, Siyan

AU - Zhang, Peiquan

AU - Wu, Jinjie

AU - Li, Xiaofen

AU - Liu, Ningning

AU - Liao, Yuning

AU - Huang, Hongbiao

AU - Shi, Xianping

AU - Jiang, Lili

AU - Liu, Xiuhua

AU - Ping Dou, Q.

AU - Wang, Xuejun

AU - Liu, Jinbao

PY - 2017/1/1

Y1 - 2017/1/1

N2 - The ubiquitin-proteasome system (UPS) plays a central role in various cellular processes through selectively degrading proteins involved in critical cellular functions. Targeting UPS has been validated as a novel strategy for treating human cancer, as inhibitors of the 20S proteasome catalytic activity are currently in clinical use for treatment of multiple myeloma and other cancers, and the deubiquitinase activity associated with the proteasome is also a valid target for anticancer agents. Recent studies suggested that zinc pyrithione, an FDA-approved antidandruff agent, may have antitumor activity, but the detailed molecular mechanisms remain unclear. Here we report that zinc pyrithione (ZnPT) targets the proteasome-associated DUBs (USP14 and UCHL5) and inhibits their activities, resulting in a rapid accumulation of protein-ubiquitin conjugates, but without inhibiting the proteolytic activities of 20S proteasomes. Furthermore, ZnPT exhibits cytotoxic effects against various cancer cell lines in vitro, selectively kills bone marrow cells from leukemia patients ex vivo, and efficiently inhibits the growth of lung adenocarcinoma cancer cell xenografts in nude mice. This study has identified zinc pyrithione, an FDA-approved pharmacological agent with potential antitumor properties as a proteasomal DUB inhibitor.

AB - The ubiquitin-proteasome system (UPS) plays a central role in various cellular processes through selectively degrading proteins involved in critical cellular functions. Targeting UPS has been validated as a novel strategy for treating human cancer, as inhibitors of the 20S proteasome catalytic activity are currently in clinical use for treatment of multiple myeloma and other cancers, and the deubiquitinase activity associated with the proteasome is also a valid target for anticancer agents. Recent studies suggested that zinc pyrithione, an FDA-approved antidandruff agent, may have antitumor activity, but the detailed molecular mechanisms remain unclear. Here we report that zinc pyrithione (ZnPT) targets the proteasome-associated DUBs (USP14 and UCHL5) and inhibits their activities, resulting in a rapid accumulation of protein-ubiquitin conjugates, but without inhibiting the proteolytic activities of 20S proteasomes. Furthermore, ZnPT exhibits cytotoxic effects against various cancer cell lines in vitro, selectively kills bone marrow cells from leukemia patients ex vivo, and efficiently inhibits the growth of lung adenocarcinoma cancer cell xenografts in nude mice. This study has identified zinc pyrithione, an FDA-approved pharmacological agent with potential antitumor properties as a proteasomal DUB inhibitor.

KW - DNA damage

KW - Deubiquitinases

KW - Proteasome

KW - Tumor

KW - Zinc pyrithione

UR - http://www.scopus.com/inward/record.url?scp=85013392290&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013392290&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.14572

DO - 10.18632/oncotarget.14572

M3 - Article

C2 - 28086217

AN - SCOPUS:85013392290

VL - 8

SP - 13942

EP - 13956

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 8

ER -